# Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

> **NCT03831698** · PHASE2 · UNKNOWN · sponsor: **University of Kansas Medical Center** · enrollment: 21 (actual)

## Conditions studied

- Colorectal Cancer
- Lynch Syndrome

## Interventions

- **DRUG:** Omega-3 fatty acid ethyl esters (2 gram)

## Key facts

- **NCT ID:** NCT03831698
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-06
- **Primary completion:** 2022-06-08
- **Final completion:** 2024-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03831698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03831698, "Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03831698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*